BI
RLMD icon

BVF Inc’s Relmada Therapeutics RLMD Stock Holding History

BVF Inc’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,078,220
Closed -$76.9M – 82
2022
Q3 		$76.9M Buy
2,078,220
+419,000
+25% +$11.6M 3.18% 8
2022
Q2 		$31.5M Buy
1,659,220
+11,820
+0.7% +$258K 1.52% 22
2022
Q1 		$44.5M Hold
1,647,400
– – 1.78% 19
2021
Q4 		$37.1M Buy
+1,647,400
New +$36.6M 1.35% 24

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BVF Inc's RLMD Position: Q4 2022 in Review

BVF Inc sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 2,078,220 shares — an estimated $76.9M sold.

BVF Inc first reported a position in RLMD in Q4 2021 and held it in 4 quarters. The position peaked at $76.9M in Q3 2022. 109 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • BVF Inc reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • BVF Inc sold 2,078,220 Relmada Therapeutics shares in Q4 2022, an estimated $76.9M.
  • BVF Inc first reported a position in Relmada Therapeutics in Q4 2021 and held it in 4 quarters.
  • BVF Inc's Relmada Therapeutics position peaked at $76.9M in Q3 2022.
  • 109 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on BVF Inc's 13F filing for Q4 2022, filed 14 Feb 2023.